Palsonify (paltusotine)
Active
Vertex Pharmaceuticals
Overview
An oral, once-daily somatostatin receptor agonist for acromegaly, acquired through the Crinetics Pharmaceuticals deal - Vertex's first marketed product outside CF, pain, and gene therapy, and the anchor of its new endocrine-disease business.
Approved in the US in September 2025 and already marketed; joined Vertex's portfolio when the Crinetics acquisition closed on September 1, 2026.